PMID- 30474478
OWN - NLM
STAT- MEDLINE
DCOM- 20200217
LR  - 20211204
IS  - 1784-973X (Electronic)
IS  - 0001-5385 (Linking)
VI  - 74
IP  - 5
DP  - 2019 Oct
TI  - Effects of sacubitril/valsartan on functional status and exercise capacity in 
      real-world patients.
PG  - 405-412
LID - 10.1080/00015385.2018.1521054 [doi]
AB  - Background: Sacubitril/valsartan significantly reduced heart failure(HF) 
      hospitalisations and mortality in the PARADIGM-HF-trial. However real-world data 
      on symptomatic and functional improvement are lacking. Methods: Between December 
      2016 and January 2018, we retrospectively collected baseline and follow-up data 
      including New York Heart Association (NYHA)-functional class and Cardio-pulmonary 
      exercise data(CPET) in all HF-patients receiving sacubitril/valsartan. 
      Additionally, in patients with an implantable electric cardiovascular device 
      (IECD) enrolled in remote telemonitoring, we quantified patient level activity 
      before and after initiation. Results: A total of 201 patients (82% males) were 
      identified. NYHA-functional class was reassessed after an average of 221 +/- 114 
      days. Overall, 3.3% of patients improved 2 NYHA classes, 28.7% improved 1 NYHA 
      class, 64% remained stable and 4% deteriorated 1 NYHA class. Patients with 
      symptomatic improvement exhibited a larger reduction in Left Ventricular End 
      Systolic Volume(LVESV) and a larger increase in Left Ventricular Ejection 
      Fraction(LVEF[p-value both <.05]). In total, 110 patients (55%) were equipped 
      with an IECD capable of quantifying outpatient activity-level. On an average of 
      364 days before sacubitril/valsartan, an activity expressed as %-of-the-day was 
      13 +/- 2%, vs. 18 +/- 3% the 364 days following sacubitril/valsartan initiation. 
      Signifying a 38% improvement in the out-patient activity level. CPET-data was 
      obtained in paired-fashion in 45 patients (22%). VO(2max) at baseline 
      (14.7 +/- 3.8 mL/kg/min) did not significantly change at follow-up 
      (14.1 +/- 4.7 mL/min/kg; p = .237). Conclusion: Real-world patients exhibit 
      significant symptomatic and functional improvement following the initiation of 
      sacubitril/valsartan. However, larger prospective studies are necessary to assess 
      the impact of sacubitril/valsartan on indices of maximal exercise performance 
      measured during CPET.
FAU - Lau, Chirik Wah
AU  - Lau CW
AD  - Department of Cardiology, Ziekenhuis Oost-Limburg , Genk , Belgium.
FAU - Martens, Pieter
AU  - Martens P
AD  - Department of Cardiology, Ziekenhuis Oost-Limburg , Genk , Belgium.
AD  - Doctoral School for Medicine and Life Sciences, Hasselt University , Diepenbeek , 
      Belgium.
FAU - Lambeets, Seppe
AU  - Lambeets S
AD  - Department of Cardiology, Ziekenhuis Oost-Limburg , Genk , Belgium.
FAU - Dupont, Matthias
AU  - Dupont M
AD  - Department of Cardiology, Ziekenhuis Oost-Limburg , Genk , Belgium.
FAU - Mullens, Wilfried
AU  - Mullens W
AD  - Department of Cardiology, Ziekenhuis Oost-Limburg , Genk , Belgium.
AD  - Faculty of Medicine and Life Sciences, Biomedical Research Institute, Hasselt 
      University , Diepenbeek , Belgium.
LA  - eng
PT  - Journal Article
DEP - 20181125
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
CIN - Acta Cardiol. 2021 Feb;76(1):107. PMID: 31920152
MH  - Aged
MH  - Aminobutyrates/*pharmacology
MH  - Angiotensin Receptor Antagonists/pharmacology
MH  - Biphenyl Compounds
MH  - Drug Combinations
MH  - Exercise Tolerance/*physiology
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Motor Activity/*physiology
MH  - Retrospective Studies
MH  - Tetrazoles/*pharmacology
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valsartan
MH  - Ventricular Function, Left/*physiology
OTO - NOTNLM
OT  - NYHA functional class
OT  - Sacubitril/valsartan
OT  - cardiopulmonary exercise test
OT  - functionality
OT  - real world
EDAT- 2018/11/27 06:00
MHDA- 2020/02/18 06:00
CRDT- 2018/11/27 06:00
PHST- 2018/11/27 06:00 [pubmed]
PHST- 2020/02/18 06:00 [medline]
PHST- 2018/11/27 06:00 [entrez]
AID - 10.1080/00015385.2018.1521054 [doi]
PST - ppublish
SO  - Acta Cardiol. 2019 Oct;74(5):405-412. doi: 10.1080/00015385.2018.1521054. Epub 
      2018 Nov 25.